NCT04857398View on ClinicalTrials.gov

A Study to Test How a New Long-acting Insulin (Insulin Icodec) Works in the Body of People From China With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 28, 2021

Primary Completion Date

April 6, 2022

Study Completion Date

April 6, 2022

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

insulin icodec

"Participants will get insulin icodec once a week for 6 weeks. The medicine will be injected under the skin.~The study will last for 15 to 22 weeks."

Trial Locations (1)

100853

Novo Nordisk Investigational Site, Beijing

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT04857398 - A Study to Test How a New Long-acting Insulin (Insulin Icodec) Works in the Body of People From China With Type 2 Diabetes | Biotech Hunter | Biotech Hunter